Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 52-Week Low – Time to Sell?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s stock price hit a new 52-week low during trading on Friday. The company traded as low as $154.30 and last traded at $157.03, with a volume of 82,046 shares changing hands. The stock had previously closed at $156.66.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ALNY. UBS Group reduced their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $329.00 and set a “buy” rating on the stock in a report on Friday, October 30th. The Goldman Sachs Group lowered their target price on shares of Alnylam Pharmaceuticals from $536.00 to $320.00 and set a “buy” rating for the company in a research note on Friday, October 30th. HC Wainwright reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 28th. Canaccord Genuity Group dropped their target price on Alnylam Pharmaceuticals from $429.00 to $323.00 and set a “buy” rating on the stock in a report on Monday. Finally, Sanford C. Bernstein cut Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $376.00 to $199.00 in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $305.86.

Alnylam Pharmaceuticals Price Performance

The stock has a market capitalization of $21.06 billion, a price-to-earnings ratio of 8.15 and a beta of 0.42. The company has a current ratio of 2.48, a quick ratio of 2.43 and a debt-to-equity ratio of 0.18. The company’s 50 day moving average is $230.18 and its 200 day moving average is $282.09.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. Alnylam Pharmaceuticals’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.90 earnings per share. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of Alnylam Pharmaceuticals by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock worth $635,296,000 after purchasing an additional 174,482 shares during the period. Legal & General Group Plc acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Alnylam Pharmaceuticals by 7.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock valued at $219,104,000 after acquiring an additional 50,329 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $148,128,000. Finally, Swiss National Bank raised its position in Alnylam Pharmaceuticals by 7.9% during the first quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company’s stock worth $128,285,000 after acquiring an additional 28,520 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.